Baumhäkel Magnus, Böhm Michael
Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.
Vasc Health Risk Manag. 2010 Apr 15;6:207-14. doi: 10.2147/vhrm.s5255.
Raynaud's phenomenon is a clinical disorder with episodic digital ischemic vasospasm triggered by cold- or emotional-stress. It was first mentioned by Maurice Raynaud in 1862 describing "a local asphyxia of the extremities" and was further divided into primary Raynaud's disease and secondary Raynaud's phenomenon, which is often related to connective tissue diseases, but also physical or chemical strain. Though pathophysiology of Raynaud's phenomenon is still poorly understood, systemic and local vascular effects are most likely to be involved in primary Raynaud's disease. In secondary Raynaud's phenomenon additional abnormalities in vascular structure and function may play the major role. Thus, medical treatment of Raynaud's phenomenon remains unsatisfactory, due to limited understanding of pathophysiological mechanisms. This review addresses current evidence for medical treatment of primary and secondary Raynaud's phenomenon with regard to pathophysiological mechanisms as well as future perspectives.
雷诺现象是一种临床疾病，由寒冷或情绪应激引发间歇性指端缺血性血管痉挛。1862年莫里斯·雷诺首次提及该病，描述为“肢体局部窒息”，后进一步分为原发性雷诺病和继发性雷诺现象，继发性雷诺现象常与结缔组织病有关，但也与物理或化学应激有关。尽管雷诺现象的病理生理学仍知之甚少，但全身和局部血管效应很可能参与原发性雷诺病。在继发性雷诺现象中，血管结构和功能的其他异常可能起主要作用。因此，由于对病理生理机制的了解有限，雷诺现象的药物治疗仍然不尽人意。本综述阐述了原发性和继发性雷诺现象药物治疗在病理生理机制方面的现有证据以及未来展望。
